APA (7th ed.) Citation

Iguchi, T., Tamada, S., Kato, M., Yasuda, S., Machida, Y., Ohmachi, T., . . . Nakatani, T. (2020). Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: The OCUU-CRPC study. International journal of clinical oncology, 25(3), 486-494. https://doi.org/10.1007/s10147-019-01554-3

Chicago Style (17th ed.) Citation

Iguchi, Taro, et al. "Enzalutamide Versus Flutamide for Castration-resistant Prostate Cancer After Combined Androgen Blockade Therapy with Bicalutamide: The OCUU-CRPC Study." International Journal of Clinical Oncology 25, no. 3 (2020): 486-494. https://doi.org/10.1007/s10147-019-01554-3.

MLA (9th ed.) Citation

Iguchi, Taro, et al. "Enzalutamide Versus Flutamide for Castration-resistant Prostate Cancer After Combined Androgen Blockade Therapy with Bicalutamide: The OCUU-CRPC Study." International Journal of Clinical Oncology, vol. 25, no. 3, 2020, pp. 486-494, https://doi.org/10.1007/s10147-019-01554-3.